Search
Search Results
-
Small-Molecule HIV Entry Inhibitors Targeting gp120 and gp41
Interrupting early events in the virus life cycle, such as those prior to the formation of provirus, could effectively prevent HIV-1 infection. HIV-1...
-
Vaccination induces broadly neutralizing antibody precursors to HIV gp41
A key barrier to the development of vaccines that induce broadly neutralizing antibodies (bnAbs) against human immunodeficiency virus (HIV) and other...
-
Recombinant Soluble Henipavirus Glycoprotein Preparation
Henipaviruses possess two envelope glycoproteins, the attachment (G) and the fusion (F) proteins that mediate cellular entry and are the major...
-
Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens
Chemical cross-linking is used to stabilize protein structures with additional benefits of pathogen and toxin inactivation for vaccine use, but its...
-
Enhancing anti-viral neutralization response to immunization with HIV-1 envelope glycoprotein immunogens
An effective human immunodeficiency virus type I (HIV-1) vaccine that robustly elicits broadly neutralizing antibodies (bnAbs) against HIV-1 envelope...
-
New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes
The main objective of the MACIVIVA European consortium was to develop new Good Manufacturing Practice pilot lines for manufacturing thermostable...
-
In vitro inhibitory effect of maraviroc on the association of the simian immunodeficiency virus envelope glycoprotein with CCR5
Asian macaques infected with simian immunodeficiency viruses (SIVs) isolated from African non-human primates develop a disease similar to human AIDS....
-
Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope
HIV-1 vaccine design aims to develop an immunogen that elicits broadly neutralizing antibodies against a desired epitope, while eliminating responses...
-
P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is incorporated into clinical HIV-1 isolates and can mediate virus capture and subsequent transfer to permissive cells
BackgroundP-selectin glycoprotein ligand-1 (PSGL-1/CD162) has been studied extensively for its role in mediating leukocyte rolling through...
-
Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines
Recombinant native-like HIV-1 envelope glycoprotein (Env) trimers are used in candidate vaccines aimed at inducing broadly neutralizing antibodies....
-
Production and Study of Immunochemical Properties of Stabilized Env Trimer of Recombinant Form CRF63_02A6 of HIV-1
Stabilized trimers of the HIV-1 envelope glycoprotein Env are capable of inducing a potent and sustained broadly neutralizing antibody response in...
-
Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry
BackgroundPeptides corresponding to N- and C-terminal heptad repeat regions (HR1 and HR2, respectively) of gp41 can inhibit HIV-1 infection in a...
-
An HIV-1 broadly neutralizing antibody overcomes structural and dynamic variation through highly focused epitope targeting
The existence of broadly cross-reactive antibodies that can neutralize diverse HIV-1 isolates (bnAbs) has been appreciated for more than a decade....
-
Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization
BackgroundNeutralizing antibodies (NAbs) protect against HIV-1 acquisition in animal models and show promise in treatment of infection. They act by...
-
Priming antibody responses to the fusion peptide in rhesus macaques
Immunodominance of antibodies targeting non-neutralizing epitopes and the high level of somatic hypermutation within germinal centers (GCs) required...
-
Fine-map** the immunodominant antibody epitopes on consensus sequence-based HIV-1 envelope trimer vaccine candidates
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutralizing antibodies (NAbs) against HIV-1. The...
-
HIV
Acquired immunodeficiency syndrome (AIDS) is a life-threatening chronic condition caused by the human immunodeficiency virus (HIV). HIV infection...
-
Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators
BackgroundWe previously developed drug-like peptide triazoles (PTs) that target HIV-1 Envelope (Env) gp120, potently inhibit viral entry, and...
-
Retrovirus
Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immunodeficiency syndrome (AIDS). AIDS is one of the most devastating...
-
Carbohydrates: Binding Sites and Potential Drug Targets for Neural-Affecting Pathogens
A number of viruses that have caused wide spread concern e.g. Ebola, Zika, and SARS-CoV2 (severe acute respiratory syndrome coronavirus 2 also known...